Literature DB >> 35284507

Two is better than one: combinatorial receptor targeting enhances hepatocellular carcinoma (HCC) therapeutic response.

Celia Sequera1, Flavio Maina1.   

Abstract

Entities:  

Year:  2022        PMID： 35284507      PMCID： PMC8847867          DOI： 10.21037/hbsn-21-517

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  14 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

Review 2.  Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.

Authors:  Flavio Maina
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 3.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

4.  Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.

Authors:  A Vogel; E Martinelli
Journal:  Ann Oncol       Date:  2021-03-05       Impact factor: 32.976

Review 5.  Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review.

Authors:  Atilla Arslanoglu; Adeel R Seyal; Faezeh Sodagari; Azize Sahin; Frank H Miller; Riad Salem; Vahid Yaghmai
Journal:  AJR Am J Roentgenol       Date:  2016-08-04       Impact factor: 3.959

6.  SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Olivier Rosmorduc; T R Jeffry Evans; Paul J Ross; Armando Santoro; Flair Jose Carrilho; Jordi Bruix; Shukui Qin; Paul J Thuluvath; Josep M Llovet; Marie-Aude Leberre; Markus Jensen; Gerold Meinhardt; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

Review 7.  Drugging the addict: non-oncogene addiction as a target for cancer therapy.

Authors:  Remco Nagel; Ekaterina A Semenova; Anton Berns
Journal:  EMBO Rep       Date:  2016-10-04       Impact factor: 8.807

8.  Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression.

Authors:  Jisan Sun; Wentao Jiang; Dazhi Tian; Qingjun Guo; Zhongyang Shen
Journal:  Onco Targets Ther       Date:  2018-11-21       Impact factor: 4.147

9.  EGFR activation limits the response of liver cancer to lenvatinib.

Authors:  Haojie Jin; Yaoping Shi; Yuanyuan Lv; Shengxian Yuan; Christel F A Ramirez; Cor Lieftink; Liqin Wang; Siying Wang; Cun Wang; Matheus Henrique Dias; Fleur Jochems; Yuan Yang; Astrid Bosma; E Marielle Hijmans; Marnix H P de Groot; Serena Vegna; Dan Cui; Yangyang Zhou; Jing Ling; Hui Wang; Yuchen Guo; Xingling Zheng; Nikita Isima; Haiqiu Wu; Chong Sun; Roderick L Beijersbergen; Leila Akkari; Weiping Zhou; Bo Zhai; Wenxin Qin; René Bernards
Journal:  Nature       Date:  2021-07-21       Impact factor: 49.962

10.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.

Authors: 
Journal:  Cell       Date:  2017-06-15       Impact factor: 66.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.